Vectorite Biomedical

Vectorite Biomedical Enterprise Value

The Enterprise Value (EV) of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is 610.61 M TWD. In the previous year, Enterprise Value (EV) was 425.71 M TWD — a change of 43.43% (higher).

Enterprise Value

610.61 MTWD

YoY

43.43%

Last updated:

Enterprise Value (EV) of Vectorite Biomedical is 2025 610.61 M TWD. Enterprise Value (EV) of Vectorite Biomedical was 2024 425.71 M TWD. It decreases by 43.43% higher compared to the previous year.

The Vectorite Biomedical Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
530.61 M TWD
Jan 1, 2019
515.56 M TWD
Jan 1, 2020
521.05 M TWD
Jan 1, 2021
371.24 M TWD
Jan 1, 2022
397.09 M TWD
Jan 1, 2023
406.94 M TWD
Jan 1, 2024
425.71 M TWD
Jan 1, 2025
610.61 M TWD
The Vectorite Biomedical Enterprise Value history
YEAREnterprise ValueYoY
610.61 MTWD+43.43%
425.71 MTWD+4.61%
406.94 MTWD+2.48%
397.09 MTWD+6.97%
371.24 MTWD-28.75%
521.05 MTWD+1.07%
515.56 MTWD-2.84%
530.61 MTWD+30.17%
407.63 MTWD-28.95%
573.69 MTWD+24.56%
460.56 MTWD+149.30%
184.74 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

Enterprise Value (EV) of Vectorite Biomedical is 610.61 M TWD in 2025.

Enterprise Value (EV) of Vectorite Biomedical changed from 425.71 M TWD to 610.61 M TWD, representing a 43.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s TWD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' TWD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Vectorite Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Vectorite Biomedical

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Vectorite Biomedical